Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.38 |
| ▸ | CDC25B | P30305 | 6/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
| ▸ | ADK | P55263 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.36 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.36 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.36 |
| ▸ | TACR2 | P21452 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14429141 | 0.87 | BCHE (0.41) | BCHEHTR1APTPN1CDC25BPDE2A | |
| SCHEMBL16316391 | 0.86 | ADK (0.46) | BCHEHTR1AADKADORA3ADORA2A | |
| SCHEMBL14429149 | 0.85 | ADORA3 (0.49) | BCHEHTR1APDE2AADORA3ADORA2A | |
| SCHEMBL14428973 | 0.83 | ADK (0.51) | BCHEHTR1APTPN1CDC25BPDE2A | |
| SCHEMBL16316386 | 0.82 | ADORA3 (0.39) | BCHEPTPN1CDC25BPDE2AADK | |
| SCHEMBL16316332 | 0.81 | ADORA3 (0.38) | BCHEPTPN1CDC25BPDE2AADK | |
| SCHEMBL14429136 | 0.79 | ADORA2A (0.56) | PDE2AADORA3ADORA2A | |
| SCHEMBL14429134 | 0.79 | ADORA2A (0.56) | PDE2AADORA3ADORA2A | |
| SCHEMBL14429128 | 0.78 | ADK (0.44) | BCHEHTR1APTPN1CDC25BPDE2A | |
| SCHEMBL1738357 | 0.78 | ADK (0.38) | ADKADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185063-A1 | Seven-membered ring nucleosides | IDENIX PHARMACEUTICALS, INC. | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185063-A1 | Seven-membered ring nucleosides | NSUN2, NSUN3, HAVCR2 | BCHE 3255/4885HTR1A 3963/4885PTPN1 4111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.